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 1 
INTRODUCTION 
                   Prostate is one of the major accessory sex gland of male 
reproductive system. The prostate is a pyramidal shaped fibromuscular 
glandular organ and it surrounds the prostatic urethra from the bladder base to 
the external urethral sphincter.The prostate was initially divided into five 
anatomical lobes in fetal life before the 20 weeks of gestation and it has 
anterior,posterior,2 lateral and middle lobe
 2
.In normal adult male only three 
lobes are present which includes two lateral lobes which can be  palpated via 
the rectum and a median lobe which projects normally into the urethra raising 
a prominence on its floor and produce crista urethralis or verumontanum. 
 
                  Prostate has exocrine functions and doubtful endocrine 
function.Prostate secretes about 0.5 ml of the total 3ml seminal fluid.It produce 
many important secretory proteins like prostate specific antigen (PSA) and 
acid phosphataset
(3)
.These two proteins  are very useful in patients with  
carcinoma prostate evaluations.  
 
                As the age increases prostate continue to enlarge in size under the 
influence of dihydrotestosterone and testosterone. Enlargement of the prostate 
can lead  to bladder outlet obstruction and produce lower urinary tract 
symptoms(LUTS). Because of the its age dependent illness, the exact 
prevalence and incidence of BPH cannot be quantified.BPH prevalence is 
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greater than 50% by the 6
th
 decade and by the 8
th
 decade BPH prevalence is as 
high as 90%.As the age increases, bother some symptoms also tends to 
increase with age and affects the quality of life.Prostate enlargement in old age 
was mentioned by various names which include benign prostatic hyperplasia 
(BPH), benign prostatic enlargement (BPE), or benign prostatic obstruction 
(BPO), benign prostatic hypertrophy, etc. Prostate enlargement produce wide 
variety of symptoms which are known as lower urinary tract symptoms.They 
can be classified as obstructive and irritative symptoms and also known as 
voiding and storage symptoms respectively.It includes hesitancy, thin stream, 
intermittency, post void dribble, decreased force of urination, straining, 
nocturia, frequency and dysuria. 
 
 LUTS are not only caused by benign prostatic enlargement and also 
caused by wide  variety of diseases.Hence,the complete evaluation of patients 
with LUTS should include the detailed history, clinical examination, per rectal 
examination followed by ultrasound, subjective assessment of symptoms in the 
form of various questionnaires(IPSS),  uroflowmetry and invasive pressure 
flow studies. 
 
 Management of the patients diagnosed with enlarged prostate due to 
benign prostatic hyperplasia depends on symptom of the patient and the 
complications of BPH.Absolute indications for the intervention in BPH are 
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recurrent infection,acute urinary retention,recurrent hematuria and 
azotemia.Various options available for  the management include are watchful 
waiting, medical management with alpha blockers or 5 alpha reductase 
inhibitors and various minimally invasive and endoscopic procedures like 
TURP, Transurethral needle ablation of prostate (TUNA), transurethral 
ultrasound–guided laser-induced prostatectomy (TULIP), transurethral 
vaporization of the prostate (TUVP), transurethral incision of prostate (TUIP) 
and open prostatectomy. 
                In the modern era of endoscopic field the need for open procedure 
becomes less and less but still it has some indications like larger prostate more 
than 75 grams, BPH with large bladder diverticulum and associated large 
vesical stone, and conditions not suitable for the lithotomy position like 
ankylosis of hip joint.Among the endoscopic procedure TURP is the “gold 
standard” treatment and  most commonly performed surgical procedure for 
benign prostatic hyperplasia. Bleeding is one of the most important intra 
operative and post operative complication in TURP.The amount of 
intraoperative bleeding depends on the volume of the prostate gland,duration 
of the surgical procedure and the surgeon‟s technique. The bleeding from the 
artery can be controlled by electrocoagulation and the perioperative blood loss 
cause haemodynamic instability and cause very much anxiety to the patient 
and its relatives.Post TURP bleeding can leads onto clot retention,urinary tract 
infection and increased the duration of hospital stay. 
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              Since the development of prostate is dependent on the 
dihydrotestosterone,androgen suppressive therapy
(4)
  can be used as the 
medical therapy for BPH.Testosterone conversion into 
dihydrotestosterone(DHT) is  inhibited by the 5alpha reductase inhibitors like 
Finasteride and Dutasteride.These drugs will inhibit the prostate 
growth.Hematuria will occur in BPH depends on the microvessel density in the 
prostatic urothelium.Several studies showed that finasteride prevents recurrent 
gross hematuria in BPH
(6)
 .Some research studies suggest that the androgen 
controlled vascular endothelial  growth factor
2
 is suppressed by finasteride and 
leads on to decreased angiogenesis.The finasteride inhibits only type2 5alpha 
reductase and the dutasteride inhibits both type1and type2 isoenzymes.So,if 
finasteride decreases TURP bleeding complication,dutasteride also can 
decrease the bleeding complication of TURP
(36)
.  
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AIM AND OBJECTIVE 
             The primary aim and objective of the present study is to determine 
whether preoperative treatment with Dutasteride decreases  surgical blood loss 
in patients who undergo  transurethral resection of the prostate for benign 
prostatic hyperplasia with prostate >30cc volume with acute urinary retention. 
The secondary objective is to assess the postoperative complication like clot 
retention,blood transfusion,failure to void after the catheter removal and the 
urinary tract infection in post operative period.    
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REVIEW OF LITERATURE 
          Benign prostatic hyperplasia is the common abnormality in more than 50 
years of age in men. Enlargement of the prostate occurs as the male becomes 
aged and cause urinary tract symptoms.Medical and surgical options are 
available for the treatment of benign prostatic hyperplasia.Eventhough various 
endoscopic procedures are available for BPH, TURP is the „gold standard‟ 
against which all other newer modalities are compared. 
 
                                              PROSTATE                                            
EMBRYOLOGY OF PROSTATE; 
              Prostate develops as a derivative of primitive endoderm during 10
th
 
week of intrauterine life. It develops distal to the bladder neck via the 
proliferation of epithelial buds extending out from the urogenital sinus 
epithelium.Prostate buds invade at stereotyped location that pattern the future 
development of distinct prostate lobes in the rodent and zones in the human. 
1)Induction of prostate budding 
                The androgen receptor signalling machinery is present throughout 
the lower genitourinary tract.But prostate epithelial buds form at precise 
location by homeobox(HOX) genes which are transcriptional regulators that 
govern differential gene expression along the craniocaudal and proximal distal 
axes in the genitourinary tract. 
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2)Mesenchymal Condensation 
                         It is mediated by gene for Noggin,Bone morphogenic 
protein(BMP) signalling which enhances mesenchymal 
condensation.Condensed mesenchyme has more expression of FGF which is 
essential for epithelial bud outgrowth.   
              By this  process the urogenital sinus mesenchymal cells become 
closely packed together.It is an androgen independent  and occurs in both male 
& female. 
3)Epithelial Budding 
                Epithelial expression of the NK homeobox transcription family 
member Nkx 3.1 is earliest indicator of prostate development at the molecular 
level
(51)
.It is an androgen dependent process.Prostate budding needs intricate 
epithelial-mesenchymal interactions.Androgens presence alone is not 
important for the development but  it should also present  in sufficient quantity 
to continue the prostatic differentiation in embryo.                                                        
ANATOMY  
       Prostate is pyramidal shaped gland located at the neck of the bladder and it 
surrounds the entire prostatic urethra.It is fibro muscular gland and lies behind 
the symphysis pubis. It measures about 3cm in length and 4cm in width and 
2cm in depth(size & shape of a chestnut). Prostate weighs about 14 to18gm   in 
normal adult male and its weight increases as the age increases. 
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           Prostatet has no true fibrous capsule which is formed by visceral layer 
of pelvic fascia.The false capsule(surgical) is formed around an area of 
adenoma by a condensation of prostatic tissue which is pushed to the periphery 
of gland.  Prostate is enclosed by visceral fascia which contains the 
neurovascular tissue. This capsule contain collagen, elastin, and more amount 
of smooth muscle.It is firmly adherent to the gland and forms numerous fibro 
muscular septa which divide the prostate glands into indistinct lobules. It is 
attached to pubis by puboprostatic ligament anteriorly and the urogenital 
diaphragm supports the inferior part of prostate. Prostate is traversed by 
urethra and posteriorly perforated by ejaculatory ducts, and it contains the 
prostatic utricle. 
 
Figure 1. Cut Section of Prostate 
 
             Prostate contains 70% glandular elements and  30%  fibro muscular 
stroma. It is made up of tubuloalveolar gland type. 
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 Lowsley classified the prostate into 5 lobes which are anterior lobe, 
posterior lobe and median lobe which project into bladder when it enlarged 
and right&left lateral lobes which are situated on both sides of the urethra.  
Franks divided the prostatic tissue with an inner (urethral) and outer glandular 
configuration. 
 
 
 
Figure 2. Zonal  anatomy of prostate – coronal plane. 
 
        McNeal and Lowsley proposed that the inner urethral glands should be 
considered separately from the prostate and its intrinsic architecture.
  
 
 According to J.E McNeal(1978), the urethra separates the prostate tissue 
into ventral or anterior part (fibromuscular) and dorsal or posterior part 
 
 
 10 
(glandular). McNeal divided the prostate into four zones : peripheral zone, 
central zone, transition zone, and periurethral gland region. 
Prostate zones
(51)
 are distinguished by, 
                1)Their duct location in the urethra 
                2)Diseases developed from the zone 
                3)By their embryologic origin 
  These prostatic zones can be seen clearly with transrectal ultrasound. 
 
 
Figure 3.Zonal anatomy of prostate – sagittal plane. 
 
           Central zone of prostate arise from Wolffian duct and other zones are 
arise from urogenital sinus. BPH commonly occurs in transitional zone and   
70% of malignancy& inflammation of prostate develops from the peripheral 
zone.  The central zone surrounds the ejaculatory duct and peripheral zone is 
cup-shaped and it encloses the central transitional zone and also the 
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preprostatic urethra except anteriorly.Adenocarcinoma of prostate  can also 
arise from the transition  zone about 20%.The central zone is rarely involved in 
any disease. 
 
 Prostate derives it blood supply through  the inferior vesical, internal 
pudendal, and middle rectal arteries. Inferior vesical artery divides into 
urethral and capsular branches.Urethral artery reach the bladder neck at 1 to 5 
o‟clock and 7 to 11 o‟clock position7 which  is important during TURP and 
open surgical procedure.Capsular branches runs posterolateral to the prostate 
in the neurovascular bundle. Prostate is drained by peri prostatic plexus which 
further drains into deep dorsal vein of penis and internal iliac veins.Prostate 
lymphatic drainage is by internal iliac, sacral and obturator nodes. 
 
BENIGN PROSTATIC HYPERPLASIA  
HISTORY 
 Urinary obstruction due to prostatic enlargement was described even in 
the olden days of medicine. The relationship between BPH and urinary outlet 
obstruction initially proposed by Riolan as early as 17
th
 century and further 
descibed by Morgagni in mid- 18
th
 century. Morgagni proposed the one of the 
earliest descriptions of BPH .
 
Virchow identified the specific pathologic 
process in 19th century. Even after the understanding the pathologic process 
exact cause BPH remains elusive.  
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AETIOPATHOGENESIS 
 Benign Prostatic Hyperplasia is  defined as “histological enlargement of 
the prostate gland from progressive hyperplasia of stromal and glandular 
prostatic cells”. Such a hyperplasia begin in the part of urethra which is 
surrounded by prostate because increased number of glandular elements in the 
above mentioned area.  
 
 Growth of the tissue occur from proliferation of the fibroblast or 
myofibroblast and epithelial glandular elements. Gland formation is usually 
occur only during gestational life. But this process of gland formation once 
again started in enlarging prostate gland is indicate that reawakening of 
inductive potential which usually only seen during fetal development.  
 
 
Figure 4.  Stromoglandular hyperplasia 
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        Aetiology of this process is not known . The process of hyperplasia 
occurs in multifocal manner and it exhibits variegated histology mixed with 
different ratios of stromal nodular and glandular hyperplastic areas.
  
 
Factors important in aetiology are,  
1. Androgens,  
2. Oestrogens,  
3. Stromal-epithelial interactions,  
4. Regulation of Programmed Cell Death 
5. Neurotransmitters  
6. Growth Factors 
 
 
HORMONAL FACTORS  
 Hormonal factors such as androgens and oestrogens are playing a role in 
the  prostate enlargement. The prostate development requires testicular 
androgens like testosterone and dihydrotestosterone (DHT). Androgens are 
required not only for proliferation and differentiation but also important for 
actively inhibiting the cell death. 
         Enzyme 5alpha-reductase which converts the hormone testosterone into 
DHT, which is the most  potent and active androgen in prostatic tissue because 
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of its increased affinity for androgen receptor(AR). Binding of androgen to AR 
leads to receptor activation and which in turn bound with particular DNA sites 
in the nucleus which results in increased transcription of androgen dependent 
genes resulting in protein synthesis. Castrations before puberty and other gene 
factors that reduce androgen production resulting in failure of development of 
BPH. Androgen withdrawal in established BPH leads to reduction in the size 
of BPH
6
. Androgen withdrawal  exert its effect by  vascular effects, 
inactivation of important androgen dependent genes like PSA and also by 
activation of important genes involved in programmed cell death.  
 
        Another hormone Oestrogen also has an unclear role as compared to its 
role in dogs where it has a role in pathogenesis of benign enlargement. 
APOPTOSIS 
 It is also  known as programmed cell death. Apoptosis is a  mechanism 
important for the normal physiological maintenance of  glandular homeostasis. 
It occurs without activation of immune mechanism. It needs RNA and protein 
synthesis. Following castration, active cell death is more in luminal epithelium  
and also in distal part of  prostatic ducts.  TNF-β family of cytokines needed 
for this process.  
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EMBRYONIC REAWAKENING THEORY 
 Paracrine type of communication is present between the stroma and 
epithelium. Stromal component defect leads to failure of normal braking 
mechanism and failure of normal cellular proliferation inhibition. This type of 
new gland occurrence in the hyperplastic prostate indicates a “reawakening” of 
embryonic processes in which underlying prostatic stroma induces epithelial 
cell development
(51)
.
 
 
GROWTH FACTORS (GF) 
 These are proteins made of peptides that stimulate, or inhibit the cell 
division and differentiation processes. Cells that respond to growth factors 
have on their responding cells and cell surface receptors are specific for that 
particular growth factor. Receptor in turn connected to a variety of trans 
membrane and intracellular signalling mechanisms. Lawson's team was the 
first to explain that extracts of BPH will increase the  cellular growth. Later 
date this  factor is identified  as basic fibroblastic growth factor (b-FGF). 
 
Stimulatory growth factors includes,  
1. Basic fibroblast growth factors  
2. Acidic  fibroblast growth factors 
3. Integrin-2  
4. Epidermal  GF  
5. Vascular endothelial growth factor (VEGF)  
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6. Keratinocyte GF  
7. Insulin-like GF 
 
Inhibitory factors, 
       1. Transforming growth factor-β - Down regulated in hyperplasia   
 
Figure 5 : Molecular control mechanisms involved in the development of 
hyperplasia 
           Inflammatory cell will produce these type of growth factors. Theyer and 
associates found  increased number of inflammatory T cells in prostatic tissue 
of patients with BPH.  
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OTHER SIGNALLING PATHWAYS 
 Sympathetic signalling pathways also has some role in the 
pathophysiology of BPH. Evidence showed that blockade of alpha recepter in 
some model systems  can induce apoptosis. Renin-angiotensin system  also are 
present in prostatic tissue and may be stimulated in BPH. 
 
 
PATHOLOGY OF BPH 
  
Figure 6 : Pathophysiology of benign prostatic hyperplasia 
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 Hyperplasia usually occurs in the periurethral transition zone of 
prostate.  When there is imbalance between death and proliferation of 
epithelial and stromal cells,it will leads  to enlargement of the prostate gland.  
It is characterised by
   
proliferation of glandular tissue which is the earliest 
change with minimal alteration of stromal elements. 
 
 Marked variability is present in stromal-epithelial ratios, such as small 
glands have predominant fibro muscular stroma and large glands demonstrate 
mainly epithelial nodules. Smooth muscles also has some important role in 
pathophysiology of BPH. 
 
 From the autopsy studies, Barry and colleagues described that BPH is a 
gradually progressive disease which commences in men in their 40 years of 
age. Baltimore Longitudinal Study of Aging suggests the progressive nature of 
the enlarged prostate in aging males. The prostate volume increase by about 
0.6 ml per year.Due to prostate enlargement,the mean fall in flow rate is about 
0.2 ml/s/year. 
 
SYMPTOMS 
       Prostate enlargement will produce  wide variety of symptoms which  are 
known as lower urinary tract symptoms and they can classified as obstructive 
and irritative. They can be called  as voiding and storage symptoms 
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respectively. The term lower urinary tract symptom (LUTS) 
(51)
 was coined by 
Paul Adams.  
OBSTRUCTIVE SYMPTOMS  
1. Hesitancy,  
2. Thin stream,  
3. Intermittency,  
4. Post void dribble, 
5. Decreased force of urination  
6. Straining 
IRRITATIVE SYMPTOMS 
1. Nocturia 
2. Frequency 
3. Dysuria 
 
EVALUATION OF BPH  
 Symptoms are the important factor to decide about the management of 
BPH, hence complete evaluation and the subjective assessment of the 
symptoms should be done. It begins with detailed history with complete and 
systematic examination including detailed per rectal examination (DRE) and 
focussed neurological examination.Complete urine analysis, culture and 
sensitivity and assessment of renal functions should be done.  
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ULTRASOUND  
 It can be done through either trans abdominal or transrectal,but trans 
abdominal USG is commonly done.Trans abdominal USG uses 3.5 MHz probe 
and high frequency 7-10 MHz probes for Trans rectal ultrasound. Volume of 
prostate calculated by depending on the shape of the prostate like if prostate is 
ellipse (π/6 × transverse diameter × AP diameter × longitudinal diameter), 
sphere (π/6 × transverse diameter3), or a prelate (egg-shaped) spheroid (π/6 × 
transverse diameter2 × AP diameter). Post void residual(PVR) urine is also 
measured in BPH evalution. 
Post void residual(PVR) Urine Volume 
       It is known as amount of fluid remaining in the bladder immediately after 
the urination.The normal PVR can varies from 0.09ml to 
2.24ml(mean;0.53ml).But in general,78% of normal men have PVR <5ml and 
100% have volume of <12ml.Post void residual urine volume is particularly 
useful for men on conservative treatment for BPH and they should be 
monitored closely & regularly.      
 
Upper urinary tract imaging is only recommended in,  
1. Patients presenting with haematuria, 
2.  Associated or suspected urinary tract infection,  
3. Elevated renal parameters  
4. History of  renal stones  
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5. Previous genito - urinary tract surgery.  
 
          In the above conditions patient may need a computerized 
tomography for the complete evaluation. Serum PSA (Prostate Specific 
Antigen) is done in patients with the family history of prostate cancer and 
suspected DRE-nodular& hard prostate enlargement.The International 
ProstateSymptom Score(IPSS) is most commonly used for the symptoms 
assessment in benign prostatic hyperplasia. This scoring system is also useful  
for evaluating patients present with LUTS. In addition to the IPSS ,objective 
assessment is done with uroflowmetry which  asses the urinary flow rate. The 
peak flow, mean flow and voiding times of the patient are measured by 
uroflowmetry test. Even though urodynamic studies are considered as gold 
standard test  for evaluating the patients with LUTS they are not routinely 
done for all BPH patients.  
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Figure 7  : Guideline algorithm  for  Evaluation of benign prostatic 
hyperplasia. 
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Urodynamic studies may be indicated in following situations, (EAU 2012) 
a. cannot void > 150 mL; 
b. When Qmax is less than 15 ml/second, 
c. Age less than 50years or more than 80years, 
d. Patients with more than 300 ml of residual urine , 
e. Suspicion of neurological bladder dysfunction, 
f. Patients with both side hydronephrosis, 
g. Previous radical surgery in pelvis, 
h. Failed invasive treatment. 
 
 EVALUATION - INTERNATIONAL PROSTATE SYMPTOM SCORE  
 It is  known as „American urological association symptom index‟ 
(AUASI). The Measurement Committee of the American urological 
association (AUA) developed the IPSS/AUASI.
(20)
 AUA/IPSS symptom score 
is reliable, validated and  most clinically useful scale to subjectively measure 
the symptoms and problem magnitude of the patients with benign enlargement 
of prostate. IPSS alone cannot be  used to confirm the diagnosis of prostate 
enlargement. By the IPSS,we can grade the symptom severity, assessment of 
responsiveness to therapy and used to detect the symptom progression in 
patients with BPH who are managed with conservative management.  
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                The IPSS score consists of seven questions corresponds to symptoms 
commonly seen in patients with BPH. They are,  
1. Incomplete emptying,  
2. Frequency,  
3. Intermittency,  
4. Urgency,  
5. Weak stream and  
6. Straining 
7. Nocturia 
 
 Every question  have zero to five points when all added together gives a 
score between zeros to thirty five. Point 0 stands for not at all patient 
experienced the symptom and 5 for almost always patient having the 
symptoms. 
 
            Based on total IPSS patients can be classified into having mild, 
moderate or severe symptoms. 
(22)
  
0-7  - Mild symptoms  
8-19  - Moderate symptoms  
20-35 - Severe symptoms  
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 Only the assessment of IPSS alone will not be helpful in confirming the 
diagnosis of BPH, because patient‟s perception of symptoms will be different  
for each  patients. Overall, the IPSS is reliable and valid through a variety of 
testing modalities.
.
 Apart from this score, varios types of scores like bother 
score and QoL index are useful in deciding the further management. 
 
QUALITY OF LIFE (QOL) INDEX  
 The QoL index  contain a single question item which can be used along 
with AUA symptom index(part of the IPSS score). QoL assess the severity to 
which the symptoms bothering the patient and the response ranges from 0-6. 
 
UROFLOWMETRY 
 Uroflowmetry is “rate of urine flow over time.” It is done by graphic 
measurement  of the urinary flow rate during the act of micturition. It is 
commonly used because it is simple, non-invasive, and easily available.Peak 
flow rate can not differentiate the BOO from impaired detrusor contractility. It 
is used as screening test for voiding problems and to decide about the more 
complex urodynamic tests requirement.  
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Modern uroflowmeters use, 
1. Use weight, (Gravimetric method) 
2. Electrical capacitance, or  
3. Rotating disc. 
 
The commonly used meters are the Gravimetric flow meters which will 
function by readding the weight of the collected urine or by reading the 
hydrostatic pressure developing at the base of the collecting cylinder 
during the act of micturition. Flow  rate  measured in ml/second. 
 
 
Figure 8- Normal bell shaped  uroflow curve 
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The AHCPR Guideline for uroflowmetry,   
1. Flow rate is not correct if patient passes less than  150 ml of urine. 
2. Flow rate is the single best non-invasive test for detecting  obstruction 
below the bladder. No “cut-off” value fixed so far. 
3. The peak flow rate (PFR; Qmax) is more specific in BPH 
4. No adjustment in values for change in age and decreasing voided 
volume. 
5.  When the Qmax > 15 mL/sec, it indicates  poorer surgical outcomes 
after prostatectomy. 
6. When A Qmax  <15 mL/sec, it  can not separate the bladder obstruction 
from decompensated bladder. 
 Qmax is  useful to predict the response to surgery. It is also useful   in 
the  follow up of patients treated for BPH. 
 
URETHROCYSTOSCOPY 
 Urethrocystoscopy is not routinely done for the BPH. It can be useful  in 
the following conditions, 
1. History of haematuria, 
2. Suspected urethral stricture disease   
3. Suspected neoplasm of bladder  
4. Prior surgery 
5. When surgical treatment is planned. 
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MANAGEMENT 
 Management of men with BPH depends on symptom severity which is 
assessed by IPSS and other associated factors and patient‟s willingness for 
given treatment.Like any other disease both medical and surgical 
managements are available apart from watchful waiting.  
 
 Watchful waiting will be useful for patients with mild or moderate IPSS 
score which is not affected the day today activities of the patient.  
 
 Treatment options are available for patients with bothersome moderate 
to severe symptoms of  BPH (IPSS > 8)  include watchful waiting and the 
medical, minimally invasive, or open surgical treatment.        
 
  In the medical management, alpha blockers or 5 alpha reductase 
inhibitors are commonly used.The various minimally invasive and endoscopic 
procedures like TURP, Transurethral needle ablation of prostate (TUNA), 
transurethral ultrasound–guided laser-induced prostatectomy (TULIP), 
transurethral vaporization of the prostate (TUVP), transurethral incision of 
prostate (TUIP) are various endoscopic options available for the treatment of 
BPH . Surgical treatment provides sustainable long term results when it is 
compare with the medical treatment in the management of BPH. 
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MEDICAL MANAGEMENT 
        For the  medical treatment of enlarged prostate, two groups of drugs like  
alpha receptor blockers and 5-alpha reductase inhibitors are available. 
(51)
  
 
          1)Alpha blockers 
                      It  act by decreasing the tone of the bladder neck and prostatic 
smooth muscle. They are divided into 
 
1. Non selective - Phenoxybenzamine                                      
2. Alpha 1 selective – Prazosin, Alfuzosin IR, Indormin. 
3. Long acting alpha I selective -   Doxazosin, Terazosin, Alfuzosin SR 
4. Super selective - Tamsulosin and Silodosin. 
 
 Most commonly used alpha blocker is Tamsulosin which is super 
selective alpha blocker.Nowdays Silodocin is also used. 
  
 
 2)The 5 alpha reductase inhibitors 
,                     It inhibits 5 alpha reductase enzyme which converts  testosterone 
into dihydrotestosterone. The drugs commonly used are finasteride and 
dutasteride. They reduces the prostate size on long term treatment and. 20% 
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reduction in volume has been reported with finasteride use alone. Eventhough 
the safety and efficacy of these drugs are well established but  the clinical 
improvement is modest and not sustainable. Patients with mild to moderate 
symptoms on drugs slowly progress into severe symptoms, may require 
surgical procedure as a definitive treatment.Pharmacotherapy will be useful in 
patients with mild symptoms and small size  prostate glands. 
 
SURGICAL MANAGEMENT 
 Endoscopic  transurethral resection of the prostate(TURP) is the most 
commonly performed surgical procedure  and this  is considered as gold 
standard for the treatment of BPH. In the initial stages, complications of TURP 
occur more commonly. But nowdays with the  available better optics, the 
complications rates are reduced. 
 
HISTORY OF ELECTROSURGERY AND THE RESECTOSCOPE 
 The invention of incandescent lamp by Edison, the cystoscope by Nitze 
and Lieter, the introduction of fenestrated tube by Hugh Hampton-Young and 
the resection wire loop by McCarthy were very important steps in the  
endourology field.It reduced the rate of open surgeries in BPH and cause less 
morbidity to the patient with good results.  
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 In 1932 McCarthy introduced tungsten loop  for resection  and it was 
developed with available cystoscope, light and electrical power and high 
resistance loop. In 1970 introduction of Hopkins rod lens system and fiberoptic 
lighting made visualization better. In 1980 video urological procedures were 
introduced. Thick loop electrode will be useful for increased coagulation while 
removing larger prostatic tissue bits.  
TURP 
  Usually, TURP is done  under spinal anaesthesia. First 
cystourethroscopy done after dilating the external urethral meatus and the 
fossa navicularis.A thorough inspection of urethra, verumontanum, prostate, 
bladder neck, entire bladder mucosa and both ureteric orifices are done.For the 
resection of the prostate, 24 Fr or 27 Fr  resectoscope is used.We use 24 Fr 
resectoscope sheath routinely. Either sterile water or glycine is used as the 
irrigant. The technique  used for resection was first described and standardised 
by Nesbit in 1943and later modified by many investigators. But the basic 
principles remain the same. They are, 
a) Controlled resection, 
b) Limiting  the resection proximal to verumontanum, 
c) Not violating the capsule and 
d) Not undermining the bladder neck  
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Complications of TURP include,  
 
1. Bleeding,  
2. Trans urethral resection  syndrome, 
3. Post -operative incontinence,  
4. Failure to void. 
Role of 5Alpha reductase inhibitors in TURP Complication;            
                Since the embryonic development of the prostate is dependent on the  
dihydrotestosterone,there is a role for the 5alpha reductase inhibitors in 
reducing the TURP complication. Finasteride is a type 2 5α-reductase 
inhibitor, and the Dutasteride is a dual inhibitor of both type 1 and type 2 5α-
reductase which are the important drugs commonly used for androgen 
suppression in BPH.
(44) 
                 Gross hematuria is rare manifestation of BPH.Many  randomized, 
double-blind, placebo-controlled study  demonstrated that Finasteride  
prevents recurrent gross hematuria secondary to BPH
10
. Gross refractory 
hematuria recurred within 1 year for 63% and 14% of men randomized to 
placebo and Finasteride, respectively. Dutasteride is a dual inhibitor of 5α- 
reductase types 1 and 2 and it has a greater impact on suppressing serum DHT 
levels
17
.Since the Finasteride was proven drug to reduce the TURP 
complication,we can expect the same role from Dutasteride also. 
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                        Impotence and decreased ejaculatory volume are the adverse 
effects from the 5ARIs.Many literature also suggests finasteride and 
dutasteride may be offered to men with hematuria secondary to friable 
prostatic tissue and in those men with LUTS due to enlarged prostate.They 
alter the natural history of urinary retention in men with enlarged prostates. 
                  
                               Antiandrogens have also been investigated for BPH.   
Many studies failed to demonstrate statistically significant treatment-related 
efficacy for antiandrogen. The equivocal efficacy and problematic toxicity of 
antiandrogens limited the enthusiasm for marketing these drugs for the 
treatment of BPH.Some studies demonsrated that Dutasteride also reduce the 
microvessel  density of prostatic tissue in TURP specimens and reduce the 
bleeding complication in TURP.R. But Shanmugasundaram et al showed that 
Dutasteride did not reduce the bleeding complication significantly when 
compared to placebo. 
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MATERIALS & METHODS 
 
 The following are the materials and methods employed for the present 
study titled :The Role Of Dutasteride In Reducing The Complications Of 
Transurethral Resection Of Prostate 
Period of study: 
     The study is done between March 2013 and Feb 2014 
 
Type: 
 This is a prospective randomised control trail study 
Place: 
 The study is conducted in the Department of Urology, Rajiv Gandhi 
Government General Hospital & Madras Medical College, Chennai. 
 
Inclusion criteria 
 Men with Benign prostate enlargement and prostate volume more than 
30cc with acute urinary retention who are undergoing TURP. 
Exclusion criteria 
 H/O prostatic surgery in the past. 
 Prostatic disease other than BPH 
 Who had 5Alpha reductase in the past 12 months 
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 Requirement of Aspirin,NSAIDS during the restricted periods, 
 Bleeding disorder, 
 Liver diseases 
 
Method of Study 
 Institutional Ethics Committee approval was obtained(EC.NO- 
31032013). Informed consent was taken from all patients who underwent 
surgery. All patient details were recorded as per the proforma(Appendix A ). 
Patients were randomized into three groups of 50 each to undergo TURP. 
Group 1-receiving placebo for two weeks preoperatively and two weeks 
postoperatively. 
Group 2-receiving Tab.Dutasteride 0.5mg BD, for 2weeks preoperatively and 
two weeks postoperatively 
Group 3-receiving Tab.Finasteride 5mg BD,two weeks preoperatively and 2 
weeks postoperatively. 
   Monopolar TURP was done with single stem TUR loop and Glycine as a 
irrigant. The settings  employed was 110W cutting and 80W coagulation for 
the  resection. 
 The setup of instruments for TURP resection, includes 24 – Fr. Karl 
Storz non-continuous flow sheath with blind and visual obturator, 
resectoscope, monopolar loop, high frequency cord, 30 degree Karl Storz 
telescope and unipolar diathermy. 
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PREOPERATIVE WORKUP 
 Complete clinical history was taken and through clinical examination 
was done for all the patients.Complete urine analysis, Urine culture and 
sensitivity were done and patients with positive cultures were treated with 
appropriate antibiotics.   Complete haemogram  and  renal function tests with 
electrolytes, coagulation parameters, Blood grouping and typing were done in  
  preoperative period.  
 
 
 
FIGURE 9 USG BLADDER WITH PROSTATE ENLARGEMENT 
X-ray KUBU and Ultra sonogram of KUB region was done for all the 
patients.The patients were randomly divided into 3groups,which each group 
consists of 50 patients.Those patients with H/O prostatic surgery in the past 
&prostatic disease other than BPH(25 in No),who had 5Alpha reductase in the 
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past 12 months(29 in No),requirement of Aspirin,NSAIDS during the 
restricted periods(12 in NO),bleeding disorder(2 in No),liver diseases(7 in No) 
were excluded( Total 55 in No).  .  
              For the Group 1 patients started placebo ,group 2 patients started 
Tab.Dutasteride 0.5mg BD,group3 patients started Tab.Finasteride 5mg BD 
two weeks preoperatively and the same treatment was continued 
postoperatively for 2weeks.The primary efficacy outcome is total blood loss 
during transurethral resection of prostate which was done under spinal 
anaesthesia.Secondary efficacy outcomes are the incidence of clot 
retention,requirement of blood transfusion,failure to void after the cathter 
removal and the incidence of urinary tract infection.All the patients were 
monitored for 2weeks in the preoperative period and 4 weeks in the 
postoperative period. 
INTRAOPERATIVE WORK UP 
          Trans Urethral Resection of Prostate was done  by the experionsed 
urologists. The resection time of TURP was calculated from the period of 
initiation of resection to the removal of resectoscope sheath.The 3 way Foley 
catheter was inserted at the end of the procedure and irrigation was started and 
continued postoperatively.  For all patients, any intraoperative complications 
and the resected prostatic tissue weight in gm were noted. The resected 
prostatic chips from the prostatic hyperplasia and the prostatic urethra were 
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send separatively for microvessel density(MVD) estimation and the 
histopathological examination. 
POSTOPERATIVE WORK UP 
          Postoperative haemoglobin and packed cell volume(PCV) were done on 
the first postoperative day after the continuous irrigation  was 
stopped.Preoperative Hb/PCV were compared with the postoperative Hb/PCV 
for the blood loss in all the three groups.Prostatic chips from the prostatic 
hyperplasia and the prostatic urothelium were fixed in 10% formalin and 
stored at 4 degree Celsius  and incubated with CD34 monoclonal 
immunohistochemical  antibody before staining wth haematoxylin& eosin.The 
most microvessels within an area of 0.754mm
2 
was counted by light 
microscopy with 200 times magnification . 
   Postoperatively all patients were monitored for haematuria,clot 
retention,blood transfusion requirement,altered sensorium,urinary tract 
infection and any change in vital parameters.Bladder Irrigation continued till 
the next morning as a protocol for all patients and the foley Catheter was 
removed on fourth postoperative day and discharged on the same day.They are 
compared with postoperative complications like clot retention,blood 
transfusion requirement,failure to void after the catheter removal and the 
urinary tract infection.Patients were reviewed with biopsy report after a week 
and all the three group patients were followed up for 4 weeks in postoperative 
period  for the TURP complication and the drug side effects. 
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STATISTICAL ANALYSIS 
 Descriptive statistics were used to illustrate the study population. The 
statistical significance of these correlations was assessed using a two sided p-
value.  A p-value of <0.05 was considered as statistically significant. The Chi 
Square test and ANOVA test were  used to assess the statistical significance. 
Multiple comparision test and paired T test  are also used for the comparision 
of various descriptive within the groups. A commercially available computer 
software package ( Statistical Package for the Social  Sciences (SPSS) version 
17) was used for statistical analysis. 
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RESULTS 
                Total of 150 patients were completed the study and the 3 randomized 
groups were compared.  
Group 1 received the placebo 2weeks preoperatively and 2 weeks 
postoperatively , 
Group 2 received the Tab.Dutasteride  0.5mg BD 2 weeks preoperatively and 2 
weeks postoperatively, 
Group 3 received the Tab.Finasteride 5 mg BD 2 weeks preoperatively and  2 
weeks postoperatively, 
Demographic data of the group 1,group 2 and group 3 are given in Table 1. 
AGE GROUP 
 YEARS  
GROUP  
1 2 3 Total 
AGE 
GROUP 
1(40-50) 
 
 
Count 1 5 1 7 
% within GROUP 2.0% 10.0% 2.0% 4.7% 
% of Total .7% 3.3% .7% 4.7% 
2(>50-60) 
 
Count 15 7 12 34 
% within GROUP 30.0% 14.0% 24.0% 22.7% 
% of Total 10.0% 4.7% 8.0% 22.7% 
3(>60-70) 
 
Count 19 26 27 72 
% within GROUP 38.0% 52.0% 54.0% 48.0% 
% of Total 12.7% 17.3% 18.0% 48.0% 
4(>70-80) 
 
Count 15 12 10 37 
% within GROUP 30.0% 24.0% 20.0% 24.7% 
% of Total 10.0% 8.0% 6.7% 24.7% 
 Total Count 50 50 50 150 
% within GROUP 100.0% 100.0% 100.0% 100.0% 
% of Total 33.3% 33.3% 33.3% 100.0% 
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Chi square=  10.064  p=  0.122  not  significant.  
 
Age group 1;40-50yrs, Group 2;>50-60 yrs,Group 3;>60-70yrs,Group 4>70 
yrs 
ANOVA 
AGE 
 Sum of Squares df Mean Square F Sig. 
Between Groups 6.173 2 3.087 .047 .954 
Within Groups 9727.000 147 66.170   
Total 9733.173 149    
As for as age is considered, it is not significant in between the 3 groups. 
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Mean age of patients in group 1,2,3 was 65.70,65.26,65.68 years 
respectively.72% in group 1,48% in group 2 and group 3 were in the 60-70 
years  which is the common age group for benign prostate enlargement.The 
maximum age in group 1,2,3 was 85,81 and 85 years respectively.As for as 
age  was considered, all the three groups were equally matched. 
DRE-GRADE   GROUPS 
   
GROUP  
1 2 3 Total 
DRE-GRADE 1 Count 22 15 21 58 
% within GROUP 44.0% 30.0% 42.0% 38.7% 
% of Total 14.7% 10.0% 14.0% 38.7% 
2 Count 28 35 29 92 
% within GROUP 56.0% 70.0% 58.0% 61.3% 
% of Total 18.7% 23.3% 19.3% 61.3% 
 Total Count 50 50 50 150 
% within GROUP 100.0% 100.0% 100.0% 100.0% 
% of Total 33.3% 33.3% 33.3% 100.0% 
Chi  square=  2.418 p= 0.299   Not  significant.  
 
 
 43 
 
In digital rectal examination, 61.3% patients had grade 2 and 38.7% had grade 
1 benign prostate enlargement.All the 3 groups  had approximately equal 
distribution of  grade 1&2 benign prostate enlargement without significant p 
value. Within the groups,smallest prostate volume is 30.09ml and the largest 
prostate volume is 65.42ml. When the prostate volume is compared in between 
the 3 groups,the mean difference was not significant. 
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Descriptives 
PROSTATE VOLUME(ml) 
  
95% Confidence Interval 
for Mean 
 N Mean 
Std. 
Deviation 
Std. Error Lower Bound Upper Bound 
1 50 40.143600 4.7211317 .6676689 38.801869 41.485331 
2 50 43.418400 8.8101061 1.2459371 40.914596 45.922204 
3 100 42.665800 9.0532749 .9053275 40.869434 44.462166 
Total 200 42.223400 8.1804135 .5784426 41.082736 43.364064 
 
PROSTATE  VOLUME 
ANOVA 
PROSTATE VOLUME(ml) 
 
 
  
 Sum of Squares df Mean Square F Sig. 
Between Groups 307.251 2 153.626 2.326 .100 
Within Groups 13009.662 197 66.039   
Total 13316.914 199    
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Multiple Comparisons 
PROSTATE VOLUME(ml)  
(I) 
GROUP 
(J) 
GROUP 
 
95% Confidence 
Interval 
Mean 
Difference (I-J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
1 2 -3.2748000
*
 1.6252864 .045 -6.479993 -.069607 
3 -2.5222000 1.4075393 .075 -5.297979 .253579 
2 1 3.2748000
*
 1.6252864 .045 .069607 6.479993 
3 .7526000 1.4075393 .593 -2.023179 3.528379 
3 1 2.5222000 1.4075393 .075 -.253579 5.297979 
2 -.7526000 1.4075393 .593 -3.528379 2.023179 
*. The mean difference is significant at the 0.05 level. 
 
.  The mean prostate volume in group1,2 and 3 were 40.14ml,43.41ml,42.66ml 
respectively. Within the groups,smallest prostate volume is 30.09ml and the 
largest prostate volume is 65.42ml. When the prostate volume was compared 
in between the all 3 groups,the mean difference was not significant. 
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Preoperative Haemoglobin  
ANOVA 
 
Sum of 
Squares 
df 
Mean 
Square 
F Sig. 
Between Groups 1.013 2 .506 3.955 .021 
Within Groups 18.822 147 .128   
Total 19.835 149    
 
PREOPERATIVE  HB 
 
 GROUP(I) 
 
GROUP
(J) 
 
95% Confidence 
Interval 
Mean Difference 
(I-J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
1 
MEAN 10.41 
2 -.168
*
 .072 .020 -.31 -.03 
3 -.180
*
 .072 .013 -.32 -.04 
2 
MEAN 10.58 
1 .168
*
 .072 .020 .03 .31 
3 -.012 .072 .867 -.15 .13 
3 
MEAN 10.59 
1 .180
*
 .072 .013 .04 .32 
2 .012 .072 .867 -.13 .15 
 
The mean difference is significant at the 0.05 level 
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Preoperative Haemoglobin. 
           The mean preoperative haemoglobin was comparable in between the 3 
groups(10.41-10.59).When the multiple comparisions were made in between 
the 3 groups,there is no significant mean difference in the preoperative 
haemoglobin level. 
Preoperative PCV 
 GROUP(I) 
 GROUP 
(J) 
 
95% Confidence 
Interval 
Mean Difference 
(I-J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
1 
MEAN 
31.08 
 
2 -.280 .223 .211 -.72 .16 
3 -.280 .223 .211 -.72 .16 
2 
MEAN 
31.36 
1 .280 .223 .211 -.16 .72 
3 .000 .223 1.000 -.44 .44 
3 
MEAN 
31.36 
1 .280 .223 .211 -.16 .72 
2 .000 .223 1.000 -.44 .44 
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PREOPERATIVE  PCV 
 Sum of Squares df Mean Square F Sig. 
Between Groups 2.613 2 1.307 1.051 .352 
Within Groups 182.720 147 1.243   
Total 185.333 149    
 
           The mean preoperative packed cell volume was comparable in between 
the 3 groups(31.08-31.36).When the multiple comparisions were made in 
between the 3 groups,there was no significant mean difference in the 
preoperative packed cell volume level.  
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TURP RESECTION TIME(mt)  Multiple Comparisons  
 GROUP(I) 
 
GROUP 
(J) 
 
95% Confidence 
Interval 
Mean 
Difference (I-J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
1 
MEAN 54.84 
2 -2.220
*
 1.038 .034 -4.27 -.17 
3 .220 1.038 .832 -1.83 2.27 
2 
MEAN 57.06 
1 2.220
*
 1.038 .034 .17 4.27 
3 2.440
*
 1.038 .020 .39 4.49 
3 
MEAN 54.62 
1 -.220 1.038 .832 -2.27 1.83 
2 -2.440
*
 1.038 .020 -4.49 -.39 
*. The mean difference is significant at the 0.05 level. 
ANOVA 
RESECTION TIME(mt) 
 
Sum of 
Squares 
df 
Mean 
Square 
F Sig. 
Between Groups 182.173 2 91.087 3.382 .037 
Within Groups 3959.320 147 26.934   
Total 4141.493 149    
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TURP RESECTION TIME 
          The mean TURP resection time was comparable in between the 3 
groups(54.62-57.06).The maximum TURP resection time  in group1,2,3 was 
68 mt,65mt and 65mt respectively.The minimum TURP resection time was 
45mt,46mt and45mt respectively.  When the multiple comparisions were made 
in between the 3 groups,there was no significant mean difference in the 
transurethral resection time of prostate. 
Multiple Comparisons 
TURP TISSUE WEIGHT (gm) 
(I) 
GROUP 
(J) 
GROUP 
 
95% Confidence 
Interval 
Mean 
Difference (I-J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
1 
MEAN 
24.8 
2 -5.800
*
 1.182 .000 -8.14 -3.46 
3 -5.640
*
 1.182 .000 -7.98 -3.30 
2 
MEAN 
30.6 
1 5.800
*
 1.182 .000 3.46 8.14 
3 .160 1.182 .893 -2.18 2.50 
3 
MEAN 
30.44 
1 5.640
*
 1.182 .000 3.30 7.98 
2 -.160 1.182 .893 -2.50 2.18 
*. The mean difference is significant at the 0.05 level. 
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ANOVA 
RESECTED  PROSTATIC  TISSUE  WEIGHT(gm) 
 Sum of Squares df Mean Square F Sig. 
Between Groups 1091.253 2 545.627 15.610 .000 
Within Groups 5138.320 147 34.955   
Total 6229.573 149    
 
The mean transurethral resected prostatic weight in group 1 is 24.8gm,group 2 
is 30.6gm and the group 3 is 30.4 gm.The maximum resected prostatic tissue 
weight was 42 gm in group 3.In the multiple comparisions,significant mean 
difference was present when the placebo group is compared with the 
Dutasteride and the Finasteride group.It indicates that large amount of 
prostatic tissue can be resected when the 5ARI is started preoperatively. 
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Multiple Comparisons 
MVD-SUBURETHRAL PROSTATIC TISSUE 
(I) 
GROUP 
(J) 
GROUP 
 
95% Confidence 
Interval 
Mean 
Difference (I-
J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
1 
MEAN 
23.315 
2 7.7548000
*
 .4873811 .000 6.791621 8.717979 
3 9.2662000
*
 .4873811 .000 8.303021 10.229379 
2 
MEAN 
15.561 
1 -7.7548000
*
 .4873811 .000 -8.717979 -6.791621 
3 1.5114000
*
 .4873811 .002 .548221 2.474579 
3 
MEAN 
14.049 
1 -9.2662000
*
 .4873811 .000 -10.229379 -8.303021 
2 -1.5114000
*
 .4873811 .002 -2.474579 -.548221 
ANOVA 
MVD-SUBURETHRAL PROSTATIC TISSUE 
 Sum of Squares df Mean Square F Sig. 
Between Groups 2471.395 2 1235.698 208.082 .000 
Within Groups 872.961 147 5.939   
Total 3344.356 149    
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Micro Vessel Density(MVD) –Suburethral Prostatic Tissue 
           The mean micro vessel density of suburethral prostatic tissue from 
Group 1, Group 2 and Group 3 were  23.3158,15.561 and 14.0496 
respectively.When multiple comparisions were made between the placebo 
group  and 5ARI groups  significant mean difference was present.It indicated 
that MVD was significantly reduced in the suburethral prostatic epithelium by 
preoperative Dutasteride and Finasteride group when compared with the 
placebo group. 
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Multiple Comparisons 
MVD-HYPERPLASTIC PROSTATICTISSUE  
(I) 
GROUP 
(J) 
GROUP 
 
95% Confidence 
Interval 
Mean 
Difference 
 (I-J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
1 
MEAN 
16.089 
2 1.4426000
*
 .1848879 .000 1.077218 1.807982 
3 3.3606000
*
 .1848879 .000 2.995218 3.725982 
2 
MEAN 
14.646 
1 -1.4426000
*
 .1848879 .000 -1.807982 -1.077218 
3 1.9180000
*
 .1848879 .000 1.552618 2.283382 
3 
MEAN 
12.728 
1 -3.3606000
*
 .1848879 .000 -3.725982 -2.995218 
2 -1.9180000
*
 .1848879 .000 -2.283382 -1.552618 
 
*. The mean difference is significant at the 0.05 level. 
ANOVA 
MVD-HYPERPLASTIC PORTION 
 Sum of Squares df Mean Square F Sig. 
Between Groups 284.224 2 142.112 166.293 .000 
Within Groups 125.624 147 .855   
Total 409.849 149    
 
 
 55 
The mean micro vessel density of hyperplastic prostatic tissue from Group 1, 
Group 2 and Group 3 were 16.089,14.646 and 12.728 respectively.When 
multiple comparisions were made between the placebo group  and Dutasteride 
,Finasteride groups, significant mean difference was present. 
 
 FIG 10 Micro vessel density CD 34 IHC- TURP PROSTATIC TISSUE 
POST OPERATIVE HB -  Multiple Comparisons 
 (I) GROUP 
(J) 
GROUP 
 
95% Confidence 
Interval 
Mean 
Difference (I-
J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
1 
MEAN 9.45 
 
2 -.1660000 .0994814 .097 -.362598 .030598 
3 -.1720000 .0994814 .086 -.368598 .024598 
2 
MEAN 9.61 
1 .1660000 .0994814 .097 -.030598 .362598 
3 -.0060000 .0994814 .952 -.202598 .190598 
3 
MEAN 9.62 
1 .1720000 .0994814 .086 -.024598 .368598 
2 .0060000 .0994814 .952 -.190598 .202598 
Placebo Group Dutasteride Group Finasteride Group 
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ANOVA 
POST OPERATIVE  HB 
 Sum of Squares df Mean Square F Sig. 
Between Groups .953 2 .476 1.926 .149 
Within Groups 36.370 147 .247   
Total 37.323 149    
 
The mean postoperative haemoglobin from Group 1,Group 2 and Group 3 is 
9.452, 9.618  and 9.624 respectively. When multiple comparisions were made 
between the placebo group  and Dutasteride ,Finasteride groups,  there was no 
significant mean difference in the post operative haemoglobin. 
 POST OPERATIVE  PCV Multiple Comparisons 
(I) 
GROUP 
(J) 
GROUP 
 
95% Confidence 
Interval 
Mean  
Difference (I-J) 
Std. 
Error 
Sig. 
Lower 
Bound 
Upper 
Bound 
1 2 -.520 .278 .063 -1.07 .03 
3 -.440 .278 .115 -.99 .11 
2 1 .520 .278 .063 -.03 1.07 
3 .080 .278 .774 -.47 .63 
3 1 .440 .278 .115 -.11 .99 
2 -.080 .278 .774 -.63 .47 
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POST OPERATIVE  PCV-ANOVA 
- 
 Sum of Squares df Mean Square F Sig. 
Between Groups 7.840 2 3.920 2.032 .135 
Within Groups 283.600 147 1.929   
Total 291.440 149    
 
                  The mean postoperative packed cell volume from Group 1,Group 2 
and Group 3 is 28.16, 28.68, 28.60  respectively. When multiple comparisions 
were made between the placebo group  and Dutasteride ,Finasteride groups,  
there was no significant mean difference in the post operative packed cell 
volume.  
Table: Paired Samples Statistics-Hb loss in TURP  
 Group 1(Placebo)  
T-Test 
  Mean N Std. Deviation 
Std. Error 
Mean 
Pair 1 PREOP HB 10.41 50 .394 .056 
POSTOP HB 9.452 50 .5697260 .0805714 
Pair 2 PREOP PCV 31.08 50 1.158 .164 
POSTOP PCV 28.16 50 1.490 .211 
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Paired Samples Test (Hb loss in GROUP 1-PLACEBO) 
Paired Differences-95% Confidence Interval of the Difference 
  Lower Upper t df 
Sig. (2-
tailed) 
Pair 1 HB - POST OP 
HB 
.7866316 1.1373684 11.024 49 .000 
Pair 2 PCV - POST OP  
PCV 
2.451 3.389 12.501 49 .000 
When the preoperative and postoperative Hb/PCV were compared in 
placebo group ,significant difference was present in the blood loss.   
Paired Samples Test(Blood loss in GROUP  2-Dutasteride) 
  Mean N Std. Deviation Std. Error Mean 
Pair 1 PREOP- HB 10.60 50 .495 .070 
POST OP -HB 9.618000 50 .4543172 .0642501 
Pair 2 PREOP-PCV 31.36 50 1.156 .164 
POST OP- PCV 28.68 50 1.406 .199 
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Paired Samples Test(  Blood loss in GROUP  2-Dutasteride) 
  Lower Upper t df 
Sig.  
(2-tailed) 
Pair 1 
  
PREOP-HB POST OP HB .8136523 1.1503477 11.722 49 .000 
Pair 2 PREOP PCV POST OP  PCV 2.252 3.108 12.598 49 .000 
 
When the preoperative and postoperative Hb/PCV were compared in the 
Dutasteride group, significant difference was present in the blood loss. 
 
Paired Samples Test(  Blood loss in GROUP 3 - Finasteride) 
  Mean N Std. Deviation Std. Error Mean 
Pair 1 HB 10.66 50 .479 .068 
POST OP HB 9.624000 50 .4596183 .0649998 
 
Pair 2 PCV 31.36 50 1.025 .145 
POST OP  PCV 28.60 50 1.262 .178 
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Paired Samples  T Test- Group 3(Finasteride) 
  
Paired Differences 
 95% Confidence  
Interval of the 
Difference 
Lower Upper t df 
Sig. (2-
tailed) 
Pair 
1 
HB - POST OP HB .8537302 1.2182698 11.422 49 .000 
Pair 
2 
PCV - POST OP  
PCV 
2.408 3.112 15.762 49 .000 
 
When the preoperative Hb/PCV and postoperative Hb/PCV were compared in 
the Finasteride group, significant difference was present in the blood loss. 
CLOT RETENTION- GROUP  Crosstab 
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Chi square=  4.001   P=  0.135,not significant 
  .  
Postoperative clot retention is occur  26%,14%,12% in Group1,2,3 
respectively without significant p value. 
TRANSFUSION * GROUP Crosstab 
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Chi  square=  2.659  P= 0.265   Not  significant. Postoperative blood 
transfusion was given 16%,10%,6% in Group 1,2,3 respectively without 
significant p value. 
 FAILURE TO VOID * GROUP- Crosstab  
 
 
 
 63 
 
Chi square=  1.500  p=  0.472  Not  significant. Postoperative failure to void 
was occur  10%,6%,4% in Group 1,2,3 respectively without significant p 
value. 
UTI * GROUP Crosstab
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 1.515
a
 2 .469 
Likelihood Ratio 1.541 2 .463 
Linear-by-Linear Association 1.505 1 .220 
N of Valid Cases 150   
 Postoperative Urinary Retention was occur in 16%,12% and 8% in group 
1,2 and 3 respectively, without  statistically significant difference . 
 
                          Postoperative urinary tract infection  was occur 16%,12%,8% 
in Group 1,2,3 respectively without significant difference. 
. 
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DISCUSSION 
 
The primary objective of this randomised controlled study was to assess 
whether preoperative treatment with Dutasteride reduces the bleeding 
complication in TURP for BPH. 
                      Many studies demonstrated that Finasteride has definite role in 
reducing the bleeding complication of TURP 
(23)
. In analysing the results of 
three groups, all the group had similar demographic  data.About 48%  patients 
are in the 60-70 age group with the mean age of 65.55. Robert G. Hahn, Tim 
Fagerström*, Teuvo L.J. Tammela et al 
(18)
 had similar study with the mean 
age of 67yrs. In the digital rectal examination  61% had Grade 2 benign 
prostate enlargement and any significant mean difference was not present 
within the groups.  
                The mean prostate volume was 42.23ml.J. A.Arratia-Maqueo et al 
had similar study which had mean prostate volume 66.8cm
3  
in Dutasteride 
group and 57cm
3
 in control group
(17)
. The mean preoperative haemoglobin was 
10.53gm/dl and the mean packed cell volume is 31.27%. The prostate 
volume,preoperative  haemoglobin and the packed cell volume didn‟t have any 
significant mean difference. 
              Robert G. Hahn, Tim Fagerström*, Teuvo L.J. Tammela et al, showed 
that the mean TURP operating time was 45 mts and the mean weight of 
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resected prostatic tissue was 25gm
(18)
 .This study also showed almost similar 
results  with the mean transurethral prostatic resection time is 55.51sec within 
the groups and the mean  transurethral resected prostatic weight was 28.61gm. 
The  mean TURP tissue weight  from the placebo, Dutasteride and Finasteride 
group was 24.8gm,30.6gm,30.4gm respectively.When the placebo group was 
compared with other groups regarding TURP tissue weight.significant mean 
difference was present.Compared to the Dutasteride,Finasteride group,in 
placebo group the mean resected prostatic tissue weight was 
less(30.6gm,30.4gm Vs 24.8 gm).It indicates that by giving preoperative 
5alpha reductase inhibitors,the resection of prostatic tissue weight in TURP 
can be increased. 
              The microvessel density(MVD) of suburethral portion of prostatic 
tissue was higher in placebo group(23.31) than in Dutasteride(15.56) and 
Finasteride group(14.04).David A A Hochberg et al showed MVD in 
Finasteride and placebo group was 20.2+5.3 Vs14.0+2.8 which was similar to 
this study.Je Hyeong Woo Korean et al showed that the mean MVD in the 
suburethral portion of prostatic tissue in Dutasteride and Placebo was 22.19 Vs 
14.47,p value 0.026. 
                The microvessel density(MVD) of hyperplastic portion of prostatic 
tissue in placebo group(16.08) was slightly higher than Dutasteride(14.64) and 
Finasteride group(12.72) in this study. Je Hyeong Woo Korean et al showed 
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that the mean MVD in the hyperplastic portion of prostatic tissue in 
Dutasteride and Placebo was 14.72 Vs 15.24,p value 0.801. David A A 
Hochberg et al showed MVD in  hyperplasti portion  in Finasteride and 
placebo group was 17.5+2.8 Vs 16.7+4.6.Je Hyeong Woo et al showed that the 
mean MVD in suburethral portion of prostatic tissue in Dutasteride treated 
patients was significantly lower than untreated patients(14.47 Vs 22.19 vessels 
per hpf,p=0.026).Some research suggests that the androgen controlled vascular 
endothelial growth factor is suppressed by 5alpha reductase inhibitors which 
was leading to decreased angiogenesis and the reduction of microvessel 
density. 
 
              Eventhough significant blood loss was present in all 3 groups due to 
TURP, when the preoperative and postoperative Hb/PCV were compared in 
between the groups and there was no statistically significant difference. The 
most practical way to quantify blood loss during TURP is by measuring Hb in 
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the irrigating fluid.Although Hb levels are only 5–10% of that found in whole 
blood, precision is ensured by using a highly sensitive photometer. In this 
study blood loss was calculated by comparing the preoperative and 
postoperative haemoglobin/PCV.    
               Postoperative clot retention from the group 1,2 and 3 was 
26%,14%,12% respectively. Postoperative blood transfusion was required in 
16%,10%,6% in groups respectively.  R.Shanmugasundaram, Nitin S.Kekre et 
all showed clot retention occurred in 6-11% and 1-3% requirement of blood 
transfusion  which was less than our study. 
                  Failure to void was occurred 10%,6%,4% in group 1,2 and group 3 
respectively.Postoperative urinary tract infection was occurred in 16%,12% 
and 8% in placepo,dutasteride and finasteride group respectively. The above 
mentioned complications were occurred in higher number in placebo group but 
there was no statistically significant differences among groups. 
R.Shanmugasundaram, Nitin S.Kekre et al showed AUR in 11-17% and UTI 
in 20-30%   statistically without significant difference 
(52)
. 
      5 Alpha reductase inhibitor like Finasteride have been commonly used in 
the perioperative period to reduce the bleeding complication in TURP.It  
shrink the prostate size by inhibiting the VEGF and decreasing the microvessel 
density.Sandfeldt et al showed that Finasteride didn‟t produce any difference 
 
 
 69 
in blood loss in TURP.Like our study,David A, A Hochberg et al showed that 
Finasteride decreases suburethral prostatic microvessel density in BPH. 
        R.Shanmugasundaram, Nitin S.Kekre et al showed that preoperative 
Dutasteride did not reduce significantly bleeding complication in TURP 
eventhough it reduced the intraprostatic concentration of DHT
(52)
.Pastore 
AL,Mariani et al showed six weeks preoperative Dutasteride treatment reduced 
the surgical bleeding in TURP.J.A.Arratia-Maqueo et al showed that no 
statistically significant difference were seen in bleeding complication in TURP 
by preoperative Dutasteride.Je Hyeong Woo et al  showed that preoperative 2 
weeks short term Dutasteride decreases suburethral prostatic microvessel 
density in BPH  and reduce the bleeding complication in TURP. 
         This randomised study  showed that 2weeks preoperative  and 2 weeks 
postoperative Dutasteride 0.5mg BD  significantly reduced the microvessel 
density in suburethral portion prostatic tissue in BPH patients and reduce the 
TURP  bleeding complications like clot retention, blood transfusion 
requirement  almost similar  by the Finasteride.   
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CONCLUSION 
 
1. The present study shows two weeks preoperative Dutasteride 0.5 mg BD 
treatment in BPH will reduce the microvessel density in suburethral 
portion of prostatic urothelium.  
2. Preoperative Dutasteride will helpful for the larger amount of prostatic 
tissue resection in lesser time.    
3. Eventhough the preoperative Haemoglobin and PCV were not 
significantly different from postoperative Hb/PCV,Dutasteride cause 
clot retention and blood transfusion in lesser number of post TURP 
patients. 
4. When the Dutasteride is compared with Finasteride in reducing the 
TURP complication,it has efficacy almost similar to the Finasteride. 
           Preoperative Dutastride will reduce the TURP complication in BPH  as 
Finasteride but needs further large randomized trials to confirm the efficacy 
with better statistically significant difference. 
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PROFORMA 
ROLE OF DUTASTERIDE IN REDUCING THE 
COMPLICATION OF TRANSURETHRAL RESECTION OF 
PROSTATE 
 
SL No:       Date: 
Patient Name:       Age/ Sex: 
IP No: 
Address: 
 
Chief Complaint: 
Presenting Illness: 
Past Medical / Surgical History:  
Personal History: 
Family History: 
General Examination: 
Pulse:       BP: 
P/A:       E/G: 
DRE: 
 
 
INVESTIGATIONS 
HB        Urine R/E: 
TC        Urine C & S: 
DC 
ESR 
RBS 
Blood Urea 
Serum Creatinine 
Serum Electrolytes 
Blood Grouping & Typing 
USG KUB 
 
Prostate Volume: 
X-Ray KUB 
Others 
S NO Name      AGE DRE-GRADE USG PROSTATE(cm) PROSTATE VOLUME(ml) HB/PCV GROUP RESEC.TIME(mt) RESEC.TISSUE(gm) MVD-SUBURETHRAL MVD-HYPERPLASTIC PORTION POST OP HB/PCV CLOT RETENTION TRANSFUSION FAILURE TO VOID UTI
1 SEBASTIN 71 GR 2 4.2X4.6X4.2 40.57 10.6/32 1 50 30 18.18 16.82 9.6/29 N N       N N
2 SANTHANAM 54 GR 2 4.1X4.4X4.0 36.08 10.2/31 1 52 28 17.18 16.34 9.8/30 N N       N N
3 VENUGOBAL 78 GR 2 4.4X4.6X4.2 42.53 10.4/32 1 55 30 20.15 15.78 10.2/31 N N       N N
4 CHINNAPPAN 65 GR 1 4.4X4.6X4.2 42.53 9.8/30 1 45 22 25.39 16.62 8.2/26 Y N       N N
5 KODHANDAN 55 GR 2 4.4X4.6X4.2 42.53  10.1/30 1 50 30 21.89 15.62 9.5/29 N N       N N
6 MUDIYAN 60 GR 2 4.3X4.5X4.1 39.67 10.2/31 1 52 29 20.87 15.72 9.7/30 N N       N N
7 VELLAI 65 GR 1 3.6X4.8X3.7 31.96 10.5/32 1 45 25 22.57 15.34 9.8/29 N N       N N
8 APPADURAI 60 GR1 3.8X4.4X3.7 30.93 10.1/30 1 46 21 21.56 16.56 9.4/28 N N       Y N
9 KANNAYIAN 55 GR2 4.1X4.6X4.4 41.49 9.9/30 1 55 30 20.63 17.56 9.6/29 N N       N N
10 PADHIRI 75 GR1 4.2X4.6X4.2 41 10.2/31 1 52 20 28.17 16.62 8.6/26 Y Y N Y
11 VEDI 55 GR1 3.7X4.4X3.8 30.93 9.4/29 1 51 24 22.89 15.88 9.2/28 N N       N N
12 ARUMUGAM 60 GR2 4.2X4.6X4.4 42.5 10.4/31 1 56 28 21.75 15.8 9.6/29 N N       N N
13 SUBRAMANI 52 GR1 3.7X4.5X3.8 31.63 11.2/34 1 47 20 20.89 14.86 10.1/30 N N       N N
14 NARASIMMAN 56 GR2 4.2X4.6X4.4 42.5 10.6/31 1 56 26 26.56 15.88 8.4/26 N Y N N
15 SIVAMOORTHY 62 GR2 4.1X4.6X4.3 40.55 11.1/33 1 53 25 22.09 15.24 10.6/31 N N       N N
16 SUBBIAH 70 GR1 4.1X4.6X4.4 40 10.2/31 1 55 22 21.67 16.62 9.8/29 N N       N Y
17 PERUMAL 73 GR2 4.0X4.5X4.3 46.44 10.4/31 1 48 23 24.12 16.56 9.6/29 Y N       N Y
18 PALAYAM 60 GR1 3.6X4.8X3.5 30.24 9.8/29 1 56 20 21.98 17.32 9.5/28 N N       N N
19 VENUGOBAL 78 GR2 4.0X4.5X4.3 38.7 10.2/31 1 56 25 21.07 14.56 9.1/27 N N       N N
20 KANNAN 72 GR1 4.1X4.6X4.3 41.2 10.6/32 1 52 23 23.1 14.98 9.8/29 N N       N N
21 MUNIKRISHNAN 62 GR1 3.9X4.6X3.8 34.08 10.2/31 1 48 24 25.5 15.76 9.4/28 Y N       Y N
22 MAHAMANI 65 GR2 4.0X4.4X4.1 36.08 10.8/32 1 56 24 21.85 15.42 9.6/29 N N       N N
23 RASAN 65 GR1 4.2X4.6X4.2 41 10.2/30 1 48 18 25.2 15.66 9.6/28 Y N       N N
24 KANNAN 77 GR2 4.1X4.8X4.6 46 9.8/29 1 58 24 22.34 16.88 9.6/28 N N       N N
25 VELU 70 GR1 4.3X4.8X4.1 43.2 10.2/31 1 55 18 27.45 16.24 8.4/25 Y Y N N
26 THIYAGARAJAN 63 GR1 4.3X4.5X4.1 39.35 11.2/33 1 56 18 22.16 16.62 10.6/31 N N       N N
27 SAMIKANNU 80 GR2 4.3X4.8X4.3 44.32 10.2/30 1 54 24 22.45 15.78 9.2/28 N N       N Y
28 ARUMUGAM 60 GR1 3.7X4.5X3.8 31.63 10.4/31 1 48 22 21.79 15.88 9.6/27 N N       N N
29 RAMALINGAM 73 GR2 4.2X4.8X4.2 42.36 10.5/31 1 66 28 28.56 16.34 8.5/26 Y Y N N
30 CHOKKALINGAN 70 GR2 4.2X4.8X4.6 46.8 10.2/30 1 58 20 22.57 16.22 9.5/29 N N       N N
31 CHELLAYAN 65 GR1 4.3X4.8X4.2 43.5 10.3/31 1 54 24 23.15 15.92 9.6/28 N N       N N
32 VEERAN 65 GR2 4.OX4.5X4.1 36.9 10.3/31 1 50 26 27.75 14.88 8.5/26 Y Y N N
33 KATHAVARAYAN 65 GR1 3.7X4.6X3.8 32.33 10.5/32 1 55 20 22.45 14.98 9.8/29 N N       N Y
34 BALARAMAN 75 GR2 4.2X4.8X4.4 44 10.4/31 1 54 24 21.87 15.62 9.8/28 N N       N N
35 PACHIAPPAN 73 GR2 4.0X4.8X4.1 39.36 10.3/31 1 52 25 21.95 16.73 9.5/28 N N       N N
36 LOGANATHAN 74 GR1 4.2X4.6X4.2 41 11.2/33 1 56 20 23.02 17.34 10.2/30 N N       N Y
37 ANUMANDHAN 82 GR2 4.2X4.6X4.3 41.54 10.4/31 1 62 34 22.54 17.12 9.6/29 N N       N N
38 RAJENDRAN 62 GR2 4.2x4.9x4.8 49.39 10.2/30 1 48 26 26.56 16.64 9.8/28 Y N       Y N
39 MANIKKAM 60 GR2 4.0X4.6X4.2 38.64 11.2/34 1 58 25 28.67 15.86 8.8/26 N Y N N
40 JEGANATHAN 65 GR1 3.8X4.6X3.7 32.33 10.5/31 1 64 20 24.12 16.34 9.8/28 Y N       N N
41 ANNAPPAN 62 GR2 4.2X4.8X4.2 42.33 10.8/31 1 65 32 25.56 16.88 9.8/28 Y N       N Y
42 ETHIRAJAN 85 GR2 4.3X4.8X4.2 43.34 10.3/30 1 68 33 22.43 15.78 9.6/28 N N       N N
43 MURUGAREDDY 67 GR1 4.3X4.8X4.2 43.5 10.8/32 1 60 20 28.23 15.92 8.6/26 Y Y N Y
44 KUPPUSAMY 65 GR2 4.1X4.5X4.2 38.74 10.2/30 1 56 28 22.43 16.64 9.8/28 N N       Y N
45 ANTHONY 65 GR1 3.8X4.8X3.9 35.56 10.4/31 1 55 20 21.78 16.62 9.7/29 N N       N N
46 PEER MOHAMED 58 GR2 4.2X4.8X4.4 44.35 10.5/30 1 65 33 28.76 16.78 8.2/25 N Y N N
47 ARUMUGAM 60 GR1 3.7X4.5X3.7 30.8 10.2/30 1 60 25 22.64 16.44 9.5/28 N N       N N
48 PERUMAL 80 GR2 4.2X4.6X4.1 39.66 11.2/33 1 56 24 25.87 15.44 8.6/25 Y N       Y N
49 SAKARABANI 45 GR1 3.6X4.4X3.9 30.88 10.6/31 1 60 25 21.76 15.92 9.5/29 N N       N N
50 AYYAKANNU 51 GR2 4.2X4.8X4.6 46.37 10.8/32 1 65 35 21.67 15.12 9.8/29 N N       N N
51 POORAN 62 GR1 3.7X4.5X3.7 30.8 10.2/30 2 58 25 16.68 14.76 9.8/28 N N       N Y
52 MANIKKAM 63 GR2 4.1X4.6X4.3 40.55 10.5/31 2 60 31 24.46 14.68 8.6/26 Y Y N N
53 VARATHARAJAN 63 GR2 4.2X4.8X4.4 44.35 10.2/30 2 56 28 15.68 15.14 9.6/28 N N       N N
54 NIRENDARADAS 63 GR2 4.2X4.9X4.5 46.3 10.5/31 2 55 30 14.62 14.96 9.5/29 N N       N N
55 MASILAMANI 50 GR2 4.2X4.8X4.6 46.37 10.2/30 2 56 32 26.78 14.42 8.6/26 Y Y N N
56 KATHAVARAYAN 60 GR2 4.5x5.2x4.8 56.16 10.4/31 2 60 40 14.68 14.76 9.6/28 N N       Y N
57 MURUGESAN 65 GR2 4.2X4.8X4.4 44.35 10.2/30 2 55 30 15.64 14.14 9.6/28 N N       N N
58 ATHIMOOLAM 50 GR2 4.6X5.2X4.7 57.4 11.2/33 2 65 39 14.68 14.88 8.6/26 N Y N N
59 PUSPARAJ 76 GR1 3.9X4.5X3.7 32.46 10.6/31 2 54 22 15.48 15.32 9.6/29 N N       N N
60 MURUGAN 65 GR2 4.2X4.8X4.5 45.36 10.5/31 2 65 34 14.58 15.42 9.8/29 N N       N N
S NO Name      AGE DRE-GRADE USG PROSTATE(cm) PROSTATE VOLUME(ml) HB/PCV GROUP RESEC.TIME(mt) RESEC.TISSUE(gm) MVD-SUBURETHRAL MVD-HYPERPLASTIC PORTION POST OP HB/PCV CLOT RETENTION TRANSFUSION FAILURE TO VOID UTI
61 SUBBURAYAN 70 GR2 4.3X4.9X4.4 46.35 10.2/30 2 60 33 20.95 15.42 8.5/25 N Y N N
62 SELVARAJ 50 GR2 4.4X4.9X4.6 49.59 10.5/31 2 62 35 14.68 14.88 9.6/28 N N       N N
63 MUNUSAMY 65 GR1 3.9X4.5X3.8 33.34 10.2/30 2 55 24 14.38 14.68 9.6/29 N N       N N
64 KANDASWAMY 77 GR2 4.2X4.8X4.3 43.34 11.2/33 2 65 32 23.34 15.42 8.4/25 Y Y N N
65 BALAKRISHNAN 65 GR2 4.1X4.6X4.3 40.55 10.8/32 2 58 29 15.68 14.88 9.8/29 N N       N N
66 DEVARAJ 74 GR2 4.6x5.4x4.9 60.85 10.3/30 2 48 36 14.68 15.42 9.7/29 N N       N N
67 VEMBULI 60 GR2 4.2X4.9X4.4 45.27 10.4/31 2 56 30 13.86 14.44 9.7/29 N N       N Y
68 KARUPPAN 70 GR1 3.8X4.6X3.8 33.21 10.3/30 2 55 23 18.68 15.62 9.5/29 Y N       Y N
69 CHOKKALINGAN 68 GR1 3.9X4.0X3.9 30.42 10.5/31 2 58 22 15.68 14.48 9.6/28 N N       N N
70 AJILU 70 GR2 4.3X4.8X4.5 46.44 11.5/34 2 65 35 16.86 15.34 9.8/29 N N       N N
71 GOPAL 67 GR2 4.5X4.9X4.4 48.51 10.7/31 2 62 34 13.68 13.88 9.8/29 N N       N N
72 SHANMUGASUNDARAM 72 GR1 3.9X4.2X3.9 31.94 10.1/30 2 48 22 17.64 13.46 9.3/28 Y N       N N
73 THIMMARAYAN 70 GR2 4.5X4.8X4.4 47.52 11.3/34 2 65 36 14.68 14.88 10.4/31 N N       N Y
74 VARATHARAJAN 63 GR2 4.2X4.8X4.6 46.37 10.8/31 2 53 30 14.34 14.88 9.9/30 N N       N N
75 CHINNPILLAI 65 GR1 3.8X4.2X3.8 30.32 10.4/31 2 57 23 13.88 15.22 9.5/29 N N       N N
76 GOVINDARAJ 64 GR2 4.8x5.2x4.9 61.15 10.4/31 2 58 38 14.46 14.48 9.8/30 N N       N Y
77 RAJAMANI 70 GR2 4.5X4.9X4.7 51.82 10.5/31 2 62 38 13.88 14.68 9.8/30 N N       N N
78 MANNANGATTI 81 GR1 3.9X4.2X3.8 31.12 10.2/30 2 48 21 15.62 13.78 9.5/29 Y N       N N
79 GOVINDARAJ 64 GR2 4.4X4.8X4.6 48.57 11.3/34 2 63 38 14.34 14.66 9.6/29 N N       N N
80 VAIYAPURI 51 GR2 4.5X4.9X4.6 50.71 11.2/33 2 57 40 13.78 15.32 10.8/32 N N       N N
81 SELVARAJ 71 GR2 4.4X4.8X4.6 48.57 10.6/31 2 54 34 14.32 14.46 9.6/29 N N       N N
82 GOVINDARAJ 64 GR1 3.9X4.3X3.9 32.7 10.3/31 2 53 25 13.68 13.66 9.7/29 N N       N N
83 MASILAMANI 56 GR2 4.4X4.8X4.7 49.63 10.8/32 2 60 35 14.46 14.14 9.6/28 N N       N N
84 ELUMALAI 65 GR2 4.2X4.7X4.6 45.4 10.5/31 2 54 23 14.64 15.12 9.8/29 N N       Y Y
85 VELLAIAPPAN 65 GR2 4.1X4.6X4.4 41.49 10.4/31 2 46 29 13.86 13.86 9.8/29 N N       N N
86 SUBRAMANI 78 GR1 3.8X4.4X3.9 32.6 10.2/30 2 50 20 14.56 14.88 9.6/28 N N       N N
87 MARIMUTHU 48 GR2 4.2X4.8X4.6 46.36 11.2/33 2 55 32 14.88 13.98 10.2/31 N N       N Y
88 AHMED BASHA 61 GR2 4.8x5.4x4.9 63.5 10.8/32 2 50 39 14.56 14.66 10.2/31 N N       N N
89 DURAIRAJ 75 GR2 4.OX4.8X4.6 44.16 11.2/33 2 65 33 15.68 14.66 10.5/31 N N       N N
90 KULLAPPAN 65 GR2 4.1X4.7X4.4 42.39 10.6/31 2 58 29 15.42 14.46 9.6/28 N N       N N
91 CHANDRAN 50 GR1 3.8X4.3X3.9 31.86 1O.2/30 2 55 23 14.68 15.62 9.5/28 N N       N N
92 MUNUSAMY 60 GR2 4.1X4.6X4.4 41.49 10.4/32 2 54 34 14.62 14.34 9.4/28 N N       N N
93 MANIKAM 65 GR1 3.9X4.6X3.9 34.98 10.2/31 2 54 24 13.68 14.78 9.6/29 N N       N N
94 DEVARAJ 60 GR2 4.4X4.8X4.5 47.52 10.8/32 2 58 38 13.86 13.98 9.7/29 N N       N N
95 SRINIVASAN 72 GR2 4.5X4.8X4.6 49.68 10.7/32 2 56 36 13.4 14.12 9.6/29 N N       N N
96 VELAYUTHAM 64 GR2 4.4X4.8X4.6 48.57 10.6/32 2 62 38 13.86 15.14 9.6/29 N N       N N
97 KRISHNAMOORTHY 58 GR1 3.8X4.3X3.8 31.04 10.5/32 2 58 23 14.34 14.86 9.8/29 N N       N N
98 SUNDARAM 80 GR1 3.9X4.4X4.0 34.32 10.5/31 2 54 25 16.86 14.38 9.6/28 Y N       N N
99 KRISHNAN 75 GR1 3.7x4.5x3.9 32.46 10.6/32 2 56 22 14.64 13.68 9.6/28 N N       N N
100 GOPAL 78 GR2 4.6X4.9X4.5 50.71 10.8/33 2 62 38 13.68 13.24 10.0/30 N N       N N
101 CHOKKALINGAN 65 GR2 4.5X4.9X4.6 50.71 10.7/31 3 58 36 13.46 14.12 9.8/29 N N       N N
102 MAHENDRAN 75 GR1 4.0x4.4x4.1 36.08 10.6/31 3 56 26 13.78 14.18 9.8/29 N N       N N
103 KASI 68 GR2 4.5X4.9X4.6 50.71 10.8/32 3 62 38 14.64 12.46 9.4/28 N N       N N
104 KRISHNAN 65 GR2 4.6X4.9X4.7 52.97 10.9/32 3 60 34 13.66 12.88 9.8/29 N N       N N
105 MEENATCHISUNDARAM 66 GR1 3.9X4.9X3.9 37.26 10.5/31 3 56 29 21.56 12.46 8.4/26 Y N       N N
106 GOVINDASWAMY 65 GR2 4.5X4.9X4.7 51.82 10.4/31 3 52 35 15.64 14.66 9.5/29 N N       N N
107 AROKIYASAMY 69 GR1 3.8X4.4X3.9 32.6 10.6/32 3 54 25 14.44 13.46 9.6/28 N N       N N
108 ANNAMALAI 55 GR2 4.8X5.8X4.7 65.42 10.8/33 3 62 42 19.46 18.96 8.8/26 Y Y N Y
109 CHAKKARAIYAH 62 GR1 3.8X4.5X3.6 30.78 10.5/31 3 56 23 14.56 15.64 9.5/29 N N       N N
110 APPARAO 75 GR2 4.6X4.9X4.6 51.84 10.8/32 3 62 38 13.66 12.88 9.6/28 N N       N N
111 MANNIKAM 75 GR1 3.8X4.4X3.7 30.93 10.6/31 3 56 22 13.88 12.46 9.8/29 N N       N N
112 RAJAN 63 GR2 4.7X4.9X4.6 52.97 10.4/32 3 54 37 14.24 13.88 9.8/29 N N       Y N
113 KOTHANDARAMAN 85 GR2 4.6X4.9X4.5 50.71 10.7/31 3 49 32 13.66 13.14 9.6/28 N N       N N
114 HARIKRISHNAN 60 GR1 3.8X4.4X3.7 30.93 10.6/32 3 48 22 12.24 12.08 9.8/29 N N       N N
115 CHANDRAMOHANRAO 65 GR2 4.4X4.9X4.6 49.58 10.8/32 3 56 39 12.14 12.04 9.8/29 N N       N N
116 ELUMALAI 63 GR2 4.2X4.7X4.3 42.44 10.7/31 3 55 33 13.24 12.46 9.7/29 N N       N N
117 PADMANABHAN 65 GR1 3.7X4.7X3.6 31.3 10.5/31 3 47 22 12.46 12.24 9.7/29 N N       N N
118 SINGARAM 78 GR2 4.7X4.9X4.6 52.97 10.6/31 3 56 33 13.24 12.68 9.8/29 N N       N N
119 RAJANGAM 60 GR2 4.5X4.9X4.6 50.71 10.2/30 3 55 36 12.86 12.12 9.4/28 N N       N N
120 KUPPANPILLAI 70 GR1 3.6X4.6X3.8 31.46 10.3/30 3 54 22 12.26 11.68 9.6/28 N N       N N
S NO Name      AGE DRE-GRADE USG PROSTATE(cm) PROSTATE VOLUME(ml) HB/PCV GROUP RESEC.TIME(mt) RESEC.TISSUE(gm) MVD-SUBURETHRAL MVD-HYPERPLASTIC PORTION POST OP HB/PCV CLOT RETENTION TRANSFUSION FAILURE TO VOID UTI
121 LOGANATHAN 80 GR2 4.6X4.8X4.5 49.68 10.2/30 3 55 36 13.26 11.98 9.8/29 N N       N N
122 ABDUL SAIT 60 GR2 4.4X4.8X4.7 49.63 10.3/31 3 52 34 12.88 11.88 9.5/29 N N       N N
123 RAMAMOORTHI 76 GR1 3.8X4.7X3.8 33.93 10.2/30 3 57 23 13.66 12.44 9.5/27 N N       N Y
124 VENKATESAN 71 GR1 3.7X4.5X3.9 32.46 10.3/31 3 56 24 12.88 12.24 9.6/28 N N       N N
125 SIVARAMAN 62 GR2 4.2X4.9X4.6 47.33 10.3/31 3 54 35 13.44 12.62 9.6/28 N N       N N
126 GOVINDARAJ 70 GR2 4.4X4.8X4.5 47.52 10.2/30 3 55 36 12.56 11.78 9.4/28 N N       N Y
127 PERUMAL 68 GR1 3.6X4.4X3.8 30.09 10.4/31 3 56 20 12.86 11.74 9.6/29 N N       N N
128 KUPPAN 70 GR2 4.4X4.8X4.3 45.4 10.5/31 3 54 38 16.88 14.68 8.5/26 N Y N N
129 SHANMUGAHAIYA 60 GR1 3.8X4.6X3.6 31.46 10.6/32 3 58 22 13.48 12.76 9.5/29 N N       N N
130 BEBUN 65 GR2 4.5X4.9X4.6 50.7 11.4/34 3 56 40 13.78 11.98 10.6/31 N N       N N
131 PALAYAM 70 GR2 4.3X4.8X4.4 45.4 11.2/33 3 49 32 14.12 12.56 9.7/29 N N       N N
132 VEERAN 65 GR1 3.8X4.7X3.8 33.93 10.8/32 3 47 23 15.88 12.68 9.8/29 Y N       N N
133 KANDAPPAREDDY 70 GR2 4.6X4.8X4.4 48.57 11.3/34 3 62 38 13.62 11.56 10.5/31 N N       N N
134 LOGANATHAN 50 GR1 3.5X4.5X3.9 30.71 10.6/31 3 46 21 14.42 13.56 9.8/29 N N       N N
135 KANNAN 55 GR1 3.6X4.7X3.9 32.99 10.2/30 3 47 23 13.56 11.44 9.5/28 Y N       N N
136 DURAI 55 GR2 4.5X4.8X4.4 47.52 10.6/31 3 53 34 13.42 12.42 9.7/28 N N       N N
137 ELUMALAI 65 GR2 4.6X4.9X4.6 51.84 11.3/33 3 65 40 13.44 11.56 10.5/31 N N       Y N
138 SUNDARAJ 57 GR1 3.7X4.8X3.8 33.74 11.2/33 3 45 24 15.46 12.46 10.5/31 N N       N N
139 BENEDICT ANTONY 64 GR2 4.4X4.9X4.6 49.58 10.7/31 3 58 34 14.48 12.46 9.8/29 N N       N N
140 NAYAGAN 76 GR1 3.8X4.7X3.8 33.93 10.2/30 3 48 21 15.66 14.68 9.5/29 N N       N N
141 ALGARSWAMY 65 GR2 4.5X4.8X4.9 52.92 10.5/31 3 53 35 14.82 12.68 8.4/25 Y N       N N
142 VENKATESAN 62 GR1 3.7X4.8X3.9 34.63 10.2/30 3 55 23 13.46 11.88 9.6/28 N N       N N
143 GANESAN 55 GR2 4.6X4.9X4.5 50.71 10.7/32 3 65 40 12.44 11.42 9.7/29 N N       N N
144 GOPAL 55 GR2 4.3X4.8X4.5 46.44 10.5/31 3 45 36 12.68 11.56 9.8/30 N N       N Y
145 DHANGARAJ 55 GR1 3.8X4.6X3.9 34.08 10.4/31 3 47 20 13.48 11.88 9.8/29 N N       N N
146 GOVINDASWAMY 60 GR1 3.7X4.6X3.9 33.18 10.2/30 3 56 23 13.44 12.24 9.7/29 N N       N N
147 KRISHNAN 75 GR2 4.2X4.8X4.3 43.34 11.2/33 3 54 30 12.66 11.86 10.2/30 N N       N N
148 RANGANATHAN 68 GR2 4.3X4.6X4.5 44.5 10.8/32 3 58 35 13.84 11.46 9.8/29 N N       N N
149 SULAIMAN 65 GR1 3.8X4.6X3.8 33.21 10.5/31 3 57 23 16.86 13.34 8.6/26 N Y N N
150 KANNAPERUMAL 66 GR2 4.5X4.8X4.6 49.68 10.2/31 3 60 35 13.98 12.14 9.5/29 Y N       N N
PATIENT CONSENT FORM 
Title of the Project 
ROLE OF DUTASTERIDE IN REDUCING THE COMPLICATION OF 
TRANSURETHRAL RESECTION OF PROSTATE 
Institution : Department of Urology, 
Madras Medical College, 
Chennai-600 003.  
Name :     Date    : 
Age  :     IP No   : 
Sex  :     Project Patient No : 
The details of the study have been provided to me in 
writing and explained to me in my own language. 
I confirm that I have understood the above study and had 
the opportunity to ask questions. 
I understood that my participation in the study is 
voluntary and that I am free to withdraw at any time, without 
giving any reason, without the medical care that will normally 
be provided by the hospital being affected. 
I agree not to restrict the use of any data or results that arise 
from this study provided such a use is only for scientific purpose(s). 
I have been given an information sheet giving details of 
the study. 
I fully consent to participate in the above study regarding 
Dutrasteride or Finasteride drug intake 2 weeks before and 
after surgery.  Transurethral resection of the prostate surgery 
(TURP) and to give the prostatic specimen for the 
investigation. 
 
__________________________ 
Name of the Subject 
_____________ 
Signature 
___________ 
Date 
   
__________________________ 
Name of the Investigator 
_____________ 
Signature 
___________ 
Date 
 INFORMATION SHEET 
Title of the Project 
ROLE OF DUTASTERIDE IN REDUCING THE COMPLICATION OF 
TRANSURETHRAL RESECTION OF PROSTATE 
 We are conducting a study on “Role of dutasteride in 
Reducing the Complication of Transurethral Resection of 
prostate” among patients attending Rajiv Gandhi 
Government General Hospital, Chennai and for that your 
co-operation may be valuable to su. 
 The privacy of the patients in the research will be 
maintained throughout the study. In the event of any 
publication or presentation resulting from the research, 
no personally identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to 
decide whether to participate in this study or to withdraw 
at any time; your decision will not result in any loss of 
benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you 
at the end of the study period or during the study if 
anything is found abnormal which may aid in the 
management or treatment. 
 You have prostate enlargement due to aging that cause 
urinary tract obstruction. During the Transurethral resection 
of prostate surgery (TURP) complication like bleeding can 
occur. To find out the role for Tab.Dutasteride in reducing 
the TURP complications, I agree to take the Dutasteride or 
Finasteride tables before and after surgery and to send the 
prostatic resected specimen for the investigation.  
 
Signature of Investigator  Signature of Participant 
Date : Date : 
jftš got« 
MŒî brŒa¥gL« jiy¥ò 
“R¡»a Ru¥ãÆ‹ (¥uhÞ£nl£) áWÚuf¤jhiu tÊÆyhd 
mWitá»¢irÆ‹ ã‹g¡fÉisîfis Fiw¥gâš oí£uirL g¤Fg‰¿a 
MŒî” 
MŒthsÇ‹ bga® : 
g¤nf‰ghsÇ‹ bga® : 
MuhŒ¢á Ãiya« : áWÚÇaš Jiw,  
br‹id kU¤Jt¡ fšÿÇ k‰W« 
uhé› fhªâ muR bghJ kU¤Jtkid, br‹id. 
j§fS¡F R¡»a Ru¥ãÆš (¥uhÞ£nl£) taJ Kâ®É‹ fhuzkhf å¡f« 
V‰g£L áWÚ® btËnaWtj‰F mil¥ò V‰g£LŸsJ. R¡»a Ru¥ãÆš 
áWÚuf¤jhiu tÊÆyhd mWit¢ á»¢irÆ‹nghJ ïu¤jfáî k‰W« 
ã‹g¡fÉisîfŸ V‰glthŒ¥òŸsJ. mªj ïu¤j fáî k‰W« 
ã‹g¡fÉisîfis Fiw¥gj‰F oí£uirL  kUªâ‹ g¤Fg‰¿ MuhŒ¢á 
brŒant©oíŸsJ. vdnt oí£uirL (m) ãdÞ£iuL kUªij mWitá»¢ir¡F 
ïu©L thu¤â‰F K‹D« ã‹D« vL¤J¡ bfhŸsî«, áWÚuf¤jhiu tÊÆyhd 
mWitá»¢ir¡F« k‰W« mWitá»¢irÆ‹ nghJ R¡»a Ru¥ãÆ‹ rijia 
MŒÉ‰F jUtj‰F« eh‹ r«kj« bjÇÉ¤J¡ bfhŸ»nw‹. 
Koîfis mšyJ fU¤Jfis btËÆL«nghnjh mšyJ MuhŒ¢áÆ‹ 
nghnjh j§fsJ bgaiunah mšyJ milahs¤fisnah btËÆlkh£nlh« 
v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«. 
ïªj MuhŒ¢áÆš g¤nf‰gJ j¤fSila ÉU¥g¤â‹ ngÇš jh‹ 
ïU¡»wJ. nkY« Ú¤fŸ vªneuK« ïªj MuhŒ¢áÆÈUªJ ã‹th¤fyh« 
v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«. 
ïªj áw¥ò gÇnrhjidfË‹ Koîfisí« nehÆ‹ j‹ik g‰¿í« 
MuhŒ¢áÆ‹nghJ mšyJ MuhŒ¢áÆ‹ KoÉ‹ nghJ j¤fS¡F m¿É¥ngh« 
v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«. 
ïªj MuhŒ¢á‹nghJ j¤fS¡F vªjÉj g¡fÉisîfŸ V‰glhJ v‹W« 
bjÇÉ¤J¡ bfhŸ»nwh«. mijí« Û¿ V‰gL« áW áW g¡fÉisîfS¡F jFªj 
áw¥ò á»¢ir ï¤F mË¡f¥gL« v‹W bjÇÉ¤J¡ bfhŸ»nwh«.  
 
g¤nf‰gtÇ‹ ifbah¥g« ……..……….. ïl«…………….. njâ…………… 
f£ilÉuš nuif 
g¤nf‰gtÇ‹ bga® k‰W« Éyhr« …………………………………………… 
MŒthsÇ‹ ifbah¥g« ……………….. ïl«…………….. njâ……………. 
MŒthsÇ‹ bga® ………………………………………… 
MuhŒ¢á x¥òjš got« 
MuhŒ¢á jiy¥ò 
R¡»a Ru¥ãÆ‹ (¥uhÞ£nl£) áWÚuf¤jhiu tÊÆyhd mWitá»¢irÆ‹ 
ã‹g¡fÉisîfis Fiw¥gâš oí£uirL g¤Fg‰¿a MŒî 
MuhŒ¢á Ãiya« :  áWÚÇaš Jiw, br‹id kU¤Jt¡ fšÿÇ, 
   uhé›fhªâ muR bghJkU¤Jtkid,     
 br‹id-600 003.  
bga® : taJ : 
MuhŒ¢á nr®¡if v© : njâ  : 
g§F bgWgt® ïjid ()  F¿¡fî« 
nkny F¿¥ã£LŸs kU¤Jt MŒÉ‹ Étu¤fŸ vd¡F 
És¡f¥g£lJ. v‹Dila rªnjf¤fis nf£fî«, mj‰fhd  jFªj 
És¡f¤fis bgwî« thŒ¥gË¡f¥g£lJ. 
eh‹ ï›thŒÉš j‹Å¢irahfjh‹ g¤nf‰»nw‹. vªj 
fhuz¤âdhnyh vªj f£l¤âY« vªj r£l á¡fY¡F« c£glhkš eh‹ 
ï›thŒÉš ïUªJ Éy» bfhŸsyh« v‹W« m¿ªJ bfh©nl‹.  
ïªj MŒî r«gªjkhfnth, ïij rh®ªj nkY« MŒî nk‰bfhŸS« 
nghJ« ïªj MŒÉš g¤FbgW« kU¤Jt® v‹Dila kU¤Jt 
m¿¡iffis gh®¥gj‰F v‹ mDkâ njitÆšiy vd m¿ªJ bfhŸ»nw‹. 
eh‹ MŒÉš ïUªJ Éy»¡ bfh©lhY« ïJ bghUªJ« vd m¿»nw‹.  
ïªj MŒÉ‹ _y« »il¡F« jftšfisí«, gÇnrhjid 
Koîfisí« k‰W« á»¢ir bjhl®ghd jftšfisí« kU¤Jt® 
nk‰bfhŸS« MŒÉš ga‹gL¤â¡bfhŸsî« mij ãuRÇ¡fî« v‹ KG 
kdJl‹ r«kâ¡»‹nw‹.  
ïªj MŒÉš g¤F bfhŸs x¥ò¡bfhŸ»nw‹. vd¡F bfhL¡f¥g£l 
m¿îiufË‹go elªJ bfhŸtJl‹ `ïªj MŒit nk‰bfhŸS« 
kU¤Jt mÂ¡F c©ikíl‹ ïU¥ng‹ v‹W cWâaË»nw‹. vdJ 
clšey« ghâ¡f¥g£lhnyh mšyJ tH¡f¤â‰F khwhd nehŒ¡F¿ 
bj‹g£lhnyh clid mij kU¤Jt mÂÆl« bjÇÉ¥ng‹ v‹W cWâ 
mË¡»nw‹.  
vd¡F MuhŒ¢á¡fhf ïu¤j¥gÇnrhjidí«, ÞnfD«, oô£uirL (m) 
ãdÞ£iuL kUªij mWit á»¢ir¡F 2 thu¤â‰F K‹D« ã‹D«, 
áWÚuf¤jhiu tÊÆyhd mWit á»¢ir¡F«, mWit¢ á»¢irÆ‹nghJ 
R¡»a Ru¥ãÆ‹ rijia MŒÉ‰F jUtj‰F« r«kâ¡»nw‹. 
 
g¤nf‰gtÇ‹ bga® g¤nf‰gtÇ‹ ifbah¥g« 
(mšyJ) f£ilÉuš nuif 
MŒths® bga® g¤nf‰ghs® ifbah¥g« 
ïl« njâ 
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